In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform recommendation. Analyst Price Forecast Suggests 195.25% Upside As of ...

The trial included 52 participants who were randomised to receive either UBX1325 10μg or aflibercept 2mg control injections every eight weeks for a six-month period post-randomisation, with the ...

values of 22 eyes with 12 moths follow-up period. + values of 45 eyes which had 3 aflibercept injections. Afl: Aflibercept, CMT: Central macular thickness. 1 Cho H, Shah CP, Weber M, Heier JS.

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 ...

"Regeneron has invested many years of effort into its design and development of EYLEA® (aflibercept) Injection 2 mg. This work has resulted in numerous patents, reflecting our important research ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing p ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...